30 Sept 2026, 5:23 pmInsider Trading / SAST
Closure of Trading Window
Closure of Trading Window PDF
Dr Lalchandani Labs Ltd operates in Healthcare Service Provider within the Healthcare sector.
947 historical price candles were omitted because the exchange source has not been verified.
No positive flags triggered.
Structured signal from quality, growth, valuation and momentum.
₹ crore, by fiscal year
% of revenue, by fiscal year
Comparable companies from the narrowest available industry classification.
Reported profit and loss, balance sheet, cash flow and growth history.
Annual operating, return, leverage and working-capital ratios.
Current futures and options contracts with compact option-chain pages.
Mutual-fund schemes that disclosed a holding in the company.
Annual reports, exchange filings, offer documents, ratings and earnings-call material.
Upcoming dates and the company’s corporate-action history.
Latest exchange announcements, filings and downloadable documents.
Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.
Standalone figures
| Ratio | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Margins | ||||||
| Gross margin % | 63.1% | 71.3% | 72.6% | 57.4% | 78.4% | 59.7% |
| EBITDA margin % | 23% | 21.4% | 1.6% | 4% | 20.7% | 1.9% |
| EBIT margin % | 17.7% | 16.1% | -11.5% | -8.9% | 8.1% | -11.7% |
| PAT margin % | 10.3% | 8.2% | -31% | 12.9% | 9.4% | 1.4% |
| Working capital | ||||||
| Receivable days | — | — | — | — | — | — |
| Inventory days | 69 | 176 | 402 | 256 | 490 | 307 |
| Payable days | — | 0 | 0 | — | — | — |
| NWC days | — | — | — | — | — | — |
| Leverage | ||||||
| Current ratio | 2.98 | 2.22 | 2.07 | 1.88 | 1.92 | 3.79 |
| Debt to EBITDA | — | 1.68 | 58.63 | — | — | — |
| Debt to equity | — | 0.39 | 0.53 | — | — | — |
| Interest coverage | 4.9 | 3.2 | -0.6 | -0.5 | 4.1 | -24.5 |
| Asset turnover | 0.64 | 0.62 | 0.28 | 0.32 | 0.28 | 0.24 |
| Return ratios | ||||||
| Return on assets % | 6.6% | 5.1% | -8.8% | 4.1% | 2.7% | 0.3% |
| Return on capital employed % | 14% | 14.2% | -4.5% | -1.7% | 3.7% | -4% |
| Return on equity % | — | 8.9% | -17.5% | — | — | — |
Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.
| Holder (%) | Sep 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| 57.18% | 48.32% | 31.15% | 32.9% | 32.9% | |
| FII | 0% | 0% | 0% | 0% | 0% |
| DII | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% |
| 42.82% | 51.68% | 68.85% | 67.1% | 67.1% | |
| No. of shareholders | 181 | 246 | 206 | 234 | 233 |
Promoter holding down 24.28 percentage points since Sep 2024.
| Date | Client | Type | Venue | Side | Quantity | Price | Value |
|---|---|---|---|---|---|---|---|
| 22 Sept 2026 | SHAILENDRA KUMAR GUPTA | Bulk | BSE | Buy | 44,000 | ₹7.81 | ₹0.03 Cr |
| 14 Aug 2026 | RAJENDRA KUMAR JAIN HUF | Bulk | BSE | Buy | 1,04,000 | ₹6.03 | ₹0.06 Cr |
| 14 Aug 2026 | SANATH KULALU | Bulk | BSE | Sell | 88,000 | ₹6.00 | ₹0.05 Cr |
| 13 Aug 2026 | SUHITH PUNDALIKA BANGERA | Bulk | BSE | Sell | 84,000 | ₹5.99 | ₹0.05 Cr |
| 11 Aug 2026 | REETHA VIKRAM | Bulk | BSE | Sell | 76,000 | ₹6.48 | ₹0.05 Cr |
| 11 Aug 2026 | SUVOJIT SARKAR | Bulk | BSE | Buy | 52,000 | ₹6.48 | ₹0.03 Cr |
| 11 Aug 2026 | SUVOJIT SARKAR | Bulk | BSE | Sell | 52,000 | ₹6.64 | ₹0.03 Cr |
| 11 Aug 2026 | PANNA LAL AND SONS HUF | Bulk | BSE | Buy | 52,000 | ₹6.48 | ₹0.03 Cr |
| 11 Aug 2026 | ANURAAG GAMBHIR | Bulk | BSE | Sell | 48,000 | ₹6.49 | ₹0.03 Cr |
| 11 Aug 2026 | ANURAAG GAMBHIR | Bulk | BSE | Buy | 32,000 | ₹6.80 | ₹0.02 Cr |
Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.
Current officeholders as filed with BSE. A person holding two offices is listed once per office.
Corporate actions, results dates and filings will appear here once ingested.
Documents link to external sources (exchange filings, company investor pages).
No scheme among the 32 fund houses on record reported a position in Dr Lalchandani Labs Ltd. Portfolios are published monthly by each AMC; coverage is still partial.
Closure of Trading Window
Extension For Annual General Meeting For FY 2025-2026
| Date | Category | Subject | Filing |
|---|---|---|---|
| 30 Sept 2026, 5:23 pm | Insider Trading / SAST Closure of Trading Window | Closure of Trading Window | |
| 17 Sept 2026, 8:27 pm | Company Update General | Extension For Annual General Meeting For FY 2025-2026 |
| Company | Mkt Cap | EV | Revenue | EBITDA | OPM | PAT | NPM | ROCE | ROE | WC Days |
|---|---|---|---|---|---|---|---|---|---|---|
| Dr. Lal Path Labs Ltd.LALPATHLABLALPATHLAB | ₹33,605 Cr | ₹33,605 Cr | ₹2,891 Cr | ₹838 Cr | 28.3% | ₹542 Cr | 18.5% | 28.8% | 21.6% | -79 |
| Vijaya Diagnostic Centre LimitedVIJAYAVIJAYA | ₹14,694 Cr | ₹14,694 Cr | ₹857 Cr | ₹362 Cr | 41.4% | ₹187 Cr | 21.3% | 21.3% | 19.7% | -117 |
| Metropolis Healthcare LimitedMETROPOLISMETROPOLIS | ₹11,151 Cr | ₹11,169 Cr | ₹1,710 Cr | ₹422 Cr | 24.4% | ₹202 Cr | 11.6% | 17.3% | 13.4% | -57 |
| Thyrocare Technologies LimitedTHYROCARETHYROCARE | ₹8,495 Cr | ₹8,495 Cr | ₹876 Cr | ₹282 Cr | 31.6% | ₹176 Cr | 19.6% | 36.5% | 28.8% | 4 |
| Nephrocare Health Services LimitedNEPHROPLUSNEPHROPLUS | ₹6,509 Cr | ₹6,589 Cr | ₹999 Cr | ₹227 Cr | 22.7% | ₹77 Cr | 7.7% | 17.1% | 9.1% | -61 |
| Suraksha Diagnostic LimitedSURAKSHASURAKSHA | ₹1,824 Cr | ₹1,826 Cr | ₹325 Cr | ₹102 Cr | 30.7% | ₹36 Cr | 10.1% | 16.8% | 14.1% | -101 |
| Krsnaa Diagnostics LimitedKRSNAAKRSNAA | ₹1,798 Cr | ₹2,332 Cr | ₹815 Cr | ₹218 Cr | 27.4% | ₹97 Cr | 13.1% | 13.1% | 10.9% | 65 |
| 3b Blackbio Dx Limited3BBLACKBIO3BBLACKBIO | ₹1,416 Cr | ₹1,417 Cr | ₹96 Cr | ₹50 Cr | 52% | ₹163 Cr | 49.4% | 25.3% | 19.4% | 235 |
| One Global Service Provider LtdONEGLOBALONEGLOBAL | ₹1,025 Cr | ₹1,025 Cr | ₹6 Cr | ₹1 Cr | 22.2% | ₹1 Cr | 17.3% | 17.6% | 19.5% | — |
| Health X Platform LimitedHEALTHXHEALTHX | ₹868 Cr | ₹890 Cr | ₹1,468 Cr | ₹-67 Cr | -4% | ₹-20 Cr | -0.1% | — | 0.2% | — |
| Gaudium Ivf And Women Health LimitedGAUDIUMIVFGAUDIUMIVF | ₹797 Cr | ₹820 Cr | ₹104 Cr | ₹38 Cr | 36.1% | ₹24 Cr | 23.4% | 23.1% | 16.1% | 92 |
| Aspira Pathlab & Diagnostics LtdASPIRAASPIRA | ₹135 Cr | ₹136 Cr | ₹22 Cr | ₹4 Cr | 16% | ₹2 Cr | 9.2% | 17.5% | 18.1% | 16 |
| ₹ Cr | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| 10 | 11 | 5 | 5 | 4 | 4 | |
| COGS | 4 | 3 | 1 | 2 | 1 | 2 |
| Gross profit | 6 | 8 | 4 | 3 | 3 | 3 |
| 4 | 6 | 4 | 3 | 3 | 2 | |
| Operating profit (EBITDA) | 2 | 2 | 0 | 0 | 1 | 0 |
| OPM % | 23% | 21.4% | 1.6% | 4% | 20.7% | 1.9% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 0 | 1 | 1 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | |
| Profit before tax | 1 | 1 | -2 | 1 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | -0 | 0 |
| Tax % | 26.8% | 24.8% | 0% | 0% | -2.5% | 30% |
| 1 | 1 | -2 | 1 | 0 | 0 | |
| PAT margin % | 10.3% | 8.2% | -31% | 12.9% | 9.4% | 1.4% |
| EPS (₹) | 2.3 | 2.2 | -3.6 | 1.4 | 1.4 | 0.1 |
| EPS adjusted (₹) | — | 2.2 | -3.6 | — | — | — |
| Annual report | Annual report for Mar 2021 | Annual report for Mar 2022 | Annual report for Mar 2023 | Annual report for Mar 2024 | Annual report for Mar 2025 | — |
| ₹ Cr | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | — | 4 | 4 | — | — | — |
| Reserves | — | 6 | 5 | — | — | — |
| — | 4 | 5 | — | — | — | |
| 15 | 4 | 4 | 15 | 16 | 18 | |
| Total equity & liabilities | 15 | 18 | 18 | 15 | 16 | 18 |
| — | — | — | — | 3 | 3 | |
| CWIP | — | — | — | — | — | — |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| 15 | 18 | 18 | 15 | 12 | 14 | |
| Total assets | 15 | 18 | 18 | 15 | 16 | 18 |
| ₹ Cr | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| 1 | 1 | -1 | -0 | 0 | -1 | |
| -2 | -1 | -0 | 1 | 0 | -1 | |
| 2 | 1 | 0 | -2 | 1 | 2 | |
| Net cash flow | 1 | 1 | -0 | -1 | 1 | 1 |
| Free cash flow | -1 | -0 | -1 | -0 | 0 | -1 |
| CFO / Operating profit % | 35.6% | 43.6% | -812.5% | -115.8% | 47.8% | -950% |